301 related articles for article (PubMed ID: 10715155)
1. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.
Wiley MR; Weir LC; Briggs S; Bryan NA; Buben J; Campbell C; Chirgadze NY; Conrad RC; Craft TJ; Ficorilli JV; Franciskovich JB; Froelich LL; Gifford-Moore DS; Goodson T; Herron DK; Klimkowski VJ; Kurz KD; Kyle JA; Masters JJ; Ratz AM; Milot G; Shuman RT; Smith T; Smith GF; Tebbe AL; Tinsley JM
J Med Chem; 2000 Mar; 43(5):883-99. PubMed ID: 10715155
[TBL] [Abstract][Full Text] [Related]
2. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
3. 1,2-Dibenzamidobenzene inhibitors of human factor Xa.
Herron DK; Goodson T; Wiley MR; Weir LC; Kyle JA; Yee YK; Tebbe AL; Tinsley JM; Mendel D; Masters JJ; Franciskovich JB; Sawyer JS; Beight DW; Ratz AM; Milot G; Hall SE; Klimkowski VJ; Wikel JH; Eastwood BJ; Towner RD; Gifford-Moore DS; Craft TJ; Smith GF
J Med Chem; 2000 Mar; 43(5):859-72. PubMed ID: 10715153
[TBL] [Abstract][Full Text] [Related]
4. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
5. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors.
Han Q; Dominguez C; Stouten PF; Park JM; Duffy DE; Galemmo RA; Rossi KA; Alexander RS; Smallwood AM; Wong PC; Wright MM; Luettgen JM; Knabb RM; Wexler RR
J Med Chem; 2000 Nov; 43(23):4398-415. PubMed ID: 11087565
[TBL] [Abstract][Full Text] [Related]
7. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groups.
Phillips G; Guilford WJ; Buckman BO; Davey DD; Eagen KA; Koovakkat S; Liang A; McCarrick M; Mohan R; Ng HP; Pinkerton M; Subramanyam B; Ho E; Trinh L; Whitlow M; Wu S; Xu W; Morrissey MM
J Med Chem; 2002 Jun; 45(12):2484-93. PubMed ID: 12036356
[TBL] [Abstract][Full Text] [Related]
9. Discovery of the factor Xa inhibitor, ZK 807834 (CI-1031).
Light DR; Guilford WJ
Curr Top Med Chem; 2001 Jun; 1(2):121-36. PubMed ID: 11899248
[TBL] [Abstract][Full Text] [Related]
10. N(2)-Aroylanthranilamide inhibitors of human factor Xa.
Yee YK; Tebbe AL; Linebarger JH; Beight DW; Craft TJ; Gifford-Moore D; Goodson T; Herron DK; Klimkowski VJ; Kyle JA; Sawyer JS; Smith GF; Tinsley JM; Towner RD; Weir L; Wiley MR
J Med Chem; 2000 Mar; 43(5):873-82. PubMed ID: 10715154
[TBL] [Abstract][Full Text] [Related]
11. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.
Dudley DA; Bunker AM; Chi L; Cody WL; Holland DR; Ignasiak DP; Janiczek-Dolphin N; McClanahan TB; Mertz TE; Narasimhan LS; Rapundalo ST; Trautschold JA; Van Huis CA; Edmunds JJ
J Med Chem; 2000 Nov; 43(22):4063-70. PubMed ID: 11063603
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
Quan ML; Ellis CD; Liauw AY; Alexander RS; Knabb RM; Lam G; Wright MR; Wong PC; Wexler RR
J Med Chem; 1999 Jul; 42(15):2760-73. PubMed ID: 10425087
[TBL] [Abstract][Full Text] [Related]
13. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids.
Sagi K; Nakagawa T; Yamanashi M; Makino S; Takahashi M; Takayanagi M; Takenaka K; Suzuki N; Oono S; Kataoka N; Ishikawa K; Shima S; Fukuda Y; Kayahara T; Takehana S; Shima Y; Tashiro K; Yamamoto H; Yoshimoto R; Iwata S; Tsuji T; Sakurai K; Shoji M
J Med Chem; 2003 May; 46(10):1845-57. PubMed ID: 12723948
[TBL] [Abstract][Full Text] [Related]
14. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
[TBL] [Abstract][Full Text] [Related]
15. New series of 6-substituted coumarin derivatives as effective factor Xa inhibitors: synthesis, in vivo antithrombotic evaluation and molecular docking.
Amin KM; Abdel Gawad NM; Abdel Rahman DE; El Ashry MK
Bioorg Chem; 2014 Feb; 52():31-43. PubMed ID: 24316885
[TBL] [Abstract][Full Text] [Related]
16. Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates.
Ishihara T; Koga Y; Mori K; Sugasawa K; Iwatsuki Y; Hirayama F
Bioorg Med Chem; 2014 Nov; 22(22):6324-32. PubMed ID: 25438755
[TBL] [Abstract][Full Text] [Related]
17. Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity.
Masters JJ; Franciskovich JB; Tinsley JM; Campbell C; Campbell JB; Craft TJ; Froelich LL; Gifford-Moore DS; Hay LA; Herron DK; Klimkowski VJ; Kurz KD; Metz JT; Ratz AM; Shuman RT; Smith GF; Smith T; Towner RD; Wiley MR; Wilson A; Yee YK
J Med Chem; 2000 Jun; 43(11):2087-92. PubMed ID: 10841787
[No Abstract] [Full Text] [Related]
18. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
[TBL] [Abstract][Full Text] [Related]
19. Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.
Choi-Sledeski YM; McGarry DG; Green DM; Mason HJ; Becker MR; Davis RS; Ewing WR; Dankulich WP; Manetta VE; Morris RL; Spada AP; Cheney DL; Brown KD; Colussi DJ; Chu V; Heran CL; Morgan SR; Bentley RG; Leadley RJ; Maignan S; Guilloteau JP; Dunwiddie CT; Pauls HW
J Med Chem; 1999 Sep; 42(18):3572-87. PubMed ID: 10479289
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1.
Quan ML; Liauw AY; Ellis CD; Pruitt JR; Carini DJ; Bostrom LL; Huang PP; Harrison K; Knabb RM; Thoolen MJ; Wong PC; Wexler RR
J Med Chem; 1999 Jul; 42(15):2752-9. PubMed ID: 10425086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
